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Abstract
Background: The predictive role of many cytokines and adhesion molecules has not been studied 
systematically in acute respiratory distress syndrome (ARDS).
Methods: We measured prospectively tumour necrosis factor alpha (TNF-α), interleukin (IL)-1, soluble 
vascular adhesion molecule-1 (VCAM-1) and soluble intercellular adhesion molecule-1 (ICAM-1) in 
serum and bronchoalveolar lavage fluid (BALF) within 2 hours following admission, in 65 patients. The 
patients were divided into: those fulfilling the criteria for ARDS (n = 23, group A), those who were pre-
ARDS and who developed ARDS within 24 hours (n = 14, group B), and those on pre-ARDS but who 
never developed ARDS (n = 28, group C).
Results: All the measured molecules were only found at higher levels in the serum of patients that died 
either with or without ARDS (P < 0.05 – P < 0.0001). Patients at risk exhibited a good negative 
predictive value (NPV) of the measured molecules for ARDS development both in their serum (89 to 
95%) and BALF (86 to 92%) levels. In contrast to BALF, serum levels of IL-1 and adhesion molecules 
exhibited a good NPV (68 to 96%), sensitivity (60 to 88%) and survival specificity (74 to 96%) in all 
groups. All molecules in serum and BALF IL-1 were correlated with the APACHE II (P < 0.05 – P < 
0.0001). Serum and BALF IL-1 as well as BALF TNF-α were negatively correlated to PaO2/FiO2 (all P
< 0.05).
Conclusions: The studied molecules have good NPV for ARDS development both in serum and BALF. 
Serum rather than BALF levels seem to be related to outcome.
Keywords: ARDS, adhesion molecules, BAL, cytokines, survival
Introduction
Acute respiratory distress syndrome (ARDS) is character-
ised during the early phase by diffuse inflammation and in-
creased microvascular permeability that cause diffused 
interstitial and alveolar oedema and persistent refractory 
hypoxemia [1]. A complex series of inflammatory events 
have been recognized during the development of ARDS 
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but the exact sequence of the events remains unclear. Most 
of our understanding regarding pulmonary inflammation in 
ARDS is based on studies regarding bronchoalveolar lav-
age fluid (BALF) [2]. Various inflammatory mediators have 
been found to be increased in BALF in the early phase of 
ARDS, including endotoxin-binding proteins, tumour necro-
sis factor alpha (TNF-α), interleukin (IL)-1, IL-6, chemok-
ines, adhesive molecules as well as matrix 
metalloproteinases and their inhibitors [2–4].
Leukocyte activation and the free radical release, proteas-
es, arachidonic acid metabolites, inflammatory and anti-in-
flammatory cytokines and TNF-α result in increased 
alveolar-capillary membrane permeability [5,3]. Cytokines 
are produced in the lung by local resident cells, such as al-
veolar macrophages, lung epithelial cells, and fibroblasts or 
by cells such as neutrophils, lymphocytes, and platelets ar-
riving there as a response to local or systemic injury [2,4–
7]. Elevated levels of proinflammatory cytokines, such as 
TNF-α and IL-1 have been found in BALF and in plasma 
from ARDS patients [8]. Furthermore, IL-8 is increased in 
BALF specimens from patients with ARDS as well as in pa-
tients at risk of developing ARDS [9]. According to various 
authors, TNF-α and IL-1 are probably produced very early 
in response to the original pathogenetic cause [2,10]. 
These early inflammatory reactions can induce the secre-
tion of chemokines and other immunomodulators by en-
dothelial cells, epithelial cells, and cells of the interstitium 
creating an intense local inflammatory response [2,10]. The 
subsequent events of these cellular/humoral interactions 
are important to the initiation and propagation of the inflam-
matory response leading to pulmonary injury [11].
The sequence of events in ARDS has been identified in an-
imal models and in pulmonary microvascular endothelial 
cell culture. In response to IL-1b and TNF-α, microvascular 
epithelium is activated and expresses intercellular adhesion 
molecule-1 (ICAM-1), vascular adhesion molecule-1 
(VCAM-1) and selectins [12,13]. The adhesion molecules 
have been found to play an important role in cell interac-
tions during inflammatory responses. ICAM-1 is induced by 
lipopolysaccharide (LPS) and cytokines such as IL-1, TNF-
α [14–16], and subsequent interactions with lymphocyte 
function-associated antigen-1 (LFA-1) mediates a wide 
range of cellular responses. VCAM-1 is also induced by cy-
tokines, such as IL-1 and mediates the adhesion of mono-
nuclear cells to the endothelium [15–17]. It has been found 
that cytokines, particularly IL-1 and TNF-α, as well as en-
dothelial cells, leukocytes and adhesion molecules appear 
to coordinate a cascade of interactions between leuko-
cytes and endothelial cells, which result in tissue injury 
[18].
To our knowledge soluble adhesion molecules have not 
been studied in ARDS although their role in other inflamma-
tory conditions is well known [19,20]. In the effort to inves-
tigate the sequence and severity of the events during the 
development of ARDS and to correlate this with clinical 
outcome, we measured soluble adhesion molecules of se-
rum and BALF in a series of 65 patients with ARDS or pre-
ARDS.
Material and methods
Patients
We studied prospectively 65 patients who were admitted 
into the intensive care unit (ICU) with severe respiratory fail-
ure. Forty patients were male with mean (SD) age 44 ± 21 
years (range, 21–77, median 55) and 25 were female with 
mean (SD) age 47 ± 18 years (range, 18–78, median 56). 
The patients were classified into 4 groups: The first group 
(group A) included 23 patients (14 male, 9 female; median 
age 53, range 18–78 years) fulfilling the criteria of ARDS 
[1]. All these patients were supported mechanically for their 
respiratory failure (PaO2/FiO2 127 ± 11, APACHE II 19.6 
± 1.1). The cause of ARDS was trauma (9), pneumonia (3), 
sepsis (5), transfusions (2), pancreatitis (2), intoxication (1), 
and burns (1).
The second group (group B) included 14 patients (8 male, 
6 female; median age 56; range 19–77 years) on mechan-
ical respiratory support who had at least one condition from 
those suggested by Fowler et al[21] as risk factors for 
ARDS development. All patients (PaO2/FiO2 235 ± 23, 
APACHE II 20.9 ± 1.3) in this group developed ARDS with-
in 48 hours. The cause of ARDS was sepsis (3), pneumo-
nia (4), trauma (6), and pancreatitis (1).
The third group (group C) included 28 patients at high risk 
for ARDS development who did not develop ARDS (18 
male, 10 female; median age 51; range 19–73 years; 
PaO2/FiO2 277 ± 21; APACHE II 17.1 ± 1.9). The cause 
of disease was trauma (15), sepsis (5), pneumonia (2), 
transfusions (2), intoxication (2), arrest (1), and pancreatitis 
(1).
The control group (group D) included 40 healthy individuals 
who had minimal surgery (e.g. lymph node biopsy, nasal di-
aphragm correction, tonsillectomy, etc.) and received an-
esthesia for a short period of time. Twenty-six were male, 
median age 35 years (range 19–70) and 14 were female, 
median age 38 years (range 25–73).
For patients' classification, the following criteria were em-
ployed:
1. the ARDS criteria of the American-European Consensus 
Conference on ARDS [1]: (a) acute onset; (b) bilateral 
chest radiographic infiltrates; (c) pulmonary artery occlu-
sion pressure of ≤ 18 mmHg, or no evidence of left atrial hy-
pertension, and (d) impaired oxygenation regardless of the Available online http://respiratory-research.com/content/3/1/25
Page 3 of 9
(page number not for citation purposes)
positive end-expiratory pressure (PEEP) concentration, 
with a PaO2/FiO2 ratio of ≤ 300 torr for acute lung injury 
(ALI) and ≤ 200 torr for ARDS;
2. the high risk criteria for ARDS development according to 
Fowler et al [21];
3. the criteria for pneumonia according to the EPIC study 
[22], and
4. the criteria for septic syndrome according to Bone et al
[23].
The Acute Physiology And Chronic Health Evaluation-II 
(APACHE II) scoring system was used for grading disease 
severity [24].
The protocol was approved by the Ethics Committee of our 
institution.
Methods
After admission to the ICU, blood samples were obtained 
from a central venous line within 2 hours. APACHE II score 
and PaO2/FiO2 values were obtained at the time of sample 
collection. The samples were obtained through a Swan-
Ganz catheter.
The blood was collected in a heparinized vacutainer tube 
and kept immediately at 4°C. After centrifugation at 1500 
g at 4°C, the plasma was kept at -80°C until measurement. 
At the same time BALF was obtained by fiberoptic bron-
choscopy. The fluid was filtered through nylon net to re-
move the mucous secretions, and centrifuged at 500 g for 
10 min to remove cells. The supernatant was kept in cryo-
tubes at -80°C in aliquots of 0.5 ml. The method of microl-
avage was used as described previously [25]. The 
following criteria were used for an acceptable sample:
(a) the procedure should be shorter than 1 min, while the 
time of saline staying in the lungs should be less than 20 s;
(b) recovery of more than 50% of the saline used for the lav-
age;
(c) absence of obvious blood contamination in the BALF, 
and
(d) the level of urea in the BALF should be more than 0.4 
mmol. The urea level was used as an index of BALF dilution 
[25,26].
Measurement of the plasma cytokines and soluble adhe-
sion molecules
The assay method for cytokine measurement was the same 
for blood and BALF samples. Determination of plasma cy-
tokines and adhesion molecules was done with the solid 
phase enzyme-linked immunosorbent assay (ELISA) meth-
odology based on the quantitative immunometric sandwich 
enzyme immunoassay technique [27,28]. Reagents for the 
various cytokines were obtained from several sources (kits 
of R&D for TNF-α, kits of Genzyme for sICAM-1, and sV-
CAM-1, and RIA kits for IL-1) and were used according to 
manufacturer's instructions. All the measurements were 
done within 6 months of the sample collection. Intra-assay 
and interassay reproducibility was checked and found to be 
more than 90%. To calculate the dilution factor of the 
BALF, urea values in the plasma and BALF were used be-
cause this low molecular weight substance is found in body 
fluids at the same concentration as in blood [29].
Statistical analysis
Data analysis was carried out using SPSS 8.0 statistical 
software (SPSS Inc., Chicago, IL). Results are expressed 
as mean ± 1 SD, or median (range), unless otherwise indi-
cated. The Mann-Whitney non-parametric test was used to 
compare the mean values of cytokines in blood and BALF 
in the various groups. Receiver Operative Characteristic 
(ROC) analysis was used to identify predictive values for 
surviving patients [30,31]. To compare the values of the 
same cytokine in the various study groups, the Kruskal-
Wallis test was used. The Spearman's rank order correla-
tion coefficient was used to determine correlation between 
the cytokines and the various other parameters measured. 
A P value < 0.05 was considered to be statistically signifi-
cant.
Results
The mean time of staying in the ICU did not differ among 
the three groups. Twelve ARDS patients (52%) died within 
15 days after submission to the ICU, while 32% of groups 
B and C (14 patients) died mainly due to respiratory failure.
Predictive capabilities of mediators for the onset of ARDS
The median values and the range of the measured cy-
tokines in BALF and serum in the three patient groups are 
shown in Table 1. BALF TNF-α levels were higher in pa-
t i e n t s  w i t h  A R D S  ( g r o u p  A )  t h a n  i n  p a t i e n t s  a t  r i s k  f o r  
ARDS (group B) and those who never developed ARDS 
(group C) (P < 0.0001 for both). On the contrary, the other 
cytokines and adhesive molecules measured in BALF were 
not significantly different among the study groups (P > 
0.05). Serum levels of sVCAM were higher in those who 
never developed ARDS (group C), while levels of the other 
cytokines and adhesive molecules were not significantly 
different.
Predictive serum and BALF levels of all studied molecules 
for ARDS development in patients at risk (groups B and C) 
are shown in Table 2. The two groups of molecules studied 
(proinflammatory cytokines and adhesion molecules) Respiratory Research   Vol 3 No 1   Agouridakis et al.
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showed good negative predictive values for ARDS devel-
opment both in serum (89 to 95%) and BALF (86 to 92%). 
In a multivariate analysis model adjusting for age and sever-
ity, none of the studied mediators were found to be an in-
dependent factor for ARDS development.
Predictive capabilities of mediators for survival
The median values and the range in BALF and serum of the 
studied mediators in survivors and non-survivors in all cate-
gories are shown in Table 3. All studied mediators were 
found at higher levels in the serum of non-survivors (IL-1, P
< 0.0001; TNF-α, P < 0.05; sICAM-1, P < 0.0001; sV-
CAM-1, P < 0.0001, respectively).
ARDS patients (group A) who did not survive had higher 
serum adhesion molecule levels than survivors (Table 4). 
Patients at risk who developed ARDS (group B) or who did 
not develop ARDS (group C) and did not survive had high-
er levels of all measured molecules in their serum (P < 0.01 
to P < 0.0001) (Table 5). Predictive serum and BALF levels 
of all studied molecules for surviving are shown in Tables 6
and 7. In contrast to BALF values, serum levels of IL-1 and 
adhesion molecules exhibited a high positive predictive val-
ue, sensitivity and specificity for surviving in all groups. In a 
multivariate analysis model adjusting for age and severity 
we found that serum IL-1 (P = 0,002) and serum ICAM-1 
(P = 0,009) were independent factors for death.
Correlations of the studied cytokines
Serum levels of all measured cytokines and adhesion mol-
ecules were significantly correlated to APACHE II score 
(Fig. 1). BALF levels of IL-1 and TNF-α were significantly 
negatively correlated to PaO2/FiO2 values (Fig. 2A and 2B, 
respectively). BALF levels of ICAM-1 (Fig. 2C) were signif-
icantly positively correlated to APACHE II scores. Serum 
Figure 1
Serum levels of IL-1 (A), TNF-α (B), ICAM-1 (C) and VCAM-1 (D) are significantly correlated to the APACHE II score. IL-1 = interleukin-1; TNF-α = 
tumour necrosis factor-alpha; ICAM-1 = intercellular adhesion molecule-1; VCAM = vascular adhesion molecule
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levels of VCAM-1 were negatively correlated to PaO2/FiO2
(Fig. 2D).
Figure 2
Bronchoalveolar lavage fluid (BALF) levels of IL-1 (A) and TNF-α (B) are significantly negatively correlated to the PaO2/FiO2 value. BALF levels of IL-
1 (C) are significantly positively correlated to the APACHE II score. Serum levels of IL-1 are negatively correlated to PaO2/FiO2 (D). IL-1 = inter-
leukin-1; TNF-α = tumour necrosis factor-alpha
Table 1 
Median (range) bronchoalveolar lavage fluid (BALF) and serum levels (pg/ml) of cytokines and adhesion molecules measured in the 
three groups of patients and controls
Group 1 (n = 23) Group 2 (n = 14) Group 3 (n = 28)
BALF Serum BALF Serum BALF Serum
IL-1 267 (0–2030) 364 (3–908) 339 (0–630) 408 (160–556) 179 (0–860) 178 (3–563)
TNF-α 463 (0–2600) 204 (60–790) 210** (0–680) 383 (160–490) 145** (0–643) 254 (93–1280)
SICAM-1 970 (540–2460) 320 (66–1120) 1440 (460–2220) 365 (220–620) 1710 (260–4620) 255 (66–900)
sVCAM 350 (156–528) 355* (66–900) 416 (92–536) 330* (180–510) 330 (52–924) 150 (66–720)
*P < 0.05 versus group 3; **P < 0.0001 versus group 1. Comparisons were done using the Kruskal-Wallis test. IL-1 = interleukin-1; TNF-α = 
tumour necrosis factor-alpha; sICAM-1 = serumintercellular adhesion molecule-1; sVCAM = serum vascular adhesion molecule
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Discussion
We investigated two categories of soluble molecules that 
might be involved in the pathogenesis of ARDS: proinflam-
matory cytokines and adhesion molecules. We studied 
these molecules within the first 2 hours of admission, in or-
der to establish factors that could have prognostic value for 
the development, severity, course and outcome of patients 
with ARDS and at risk of ARDS.
The interesting finding of this study was that all the meas-
ured molecules were found at significantly higher levels 
only in the serum of patients that died either with or without 
ARDS (P < 0.05 to P < 0.0001) (Table 3). We also found 
that the proinflammatory cytokine TNF-α was elevated in 
the BALF of ARDS patients compared to at risk patients, 
confirming previous observations [30,31]. The most likely 
explanation is that the increased TNF-α and IL-1 levels 
found in the BALF of our patients were produced by acti-
vated pulmonary macrophages or other cells. These cells 
are located in lung interstitium, alveolar space and capillar-
ies in humans [2,32–35]. It is known that endothelial cell 
activation and VCAM-1 expression is induced mainly by IL-
1b and TNF-α. However, the levels of TNF-α and IL-1 were 
not predictive for the development of the syndrome.
BALF soluble adhesion molecules sICAM and sVCAM did 
not differ among the three groups of patients. This means 
that lung endothelial cell inflammation existed in all the crit-
ically ill patients studied. It seems that endothelial damage 
alone is not enough for cell extravasation in the interstitium 
but the presence of a continuous chemotactic gradient is 
also essential; this gradient is produced by IL-6, IL-8 and 
possibly other C-X-C chemokines that are secreted by res-
ident cells upon activation or arrive there through the circu-
lation [6,7,32].
Table 2 
Predictive (%) serum and bronchoalveolar lavage fluid (BALF) levels (pg/ml) of the measured cytokines and adhesion molecules for 
acute respiratory distress syndrome development in patients at risk (n = 42)
Criterion PPV NPV Sensitivity Specificity 95% CI
Serum
IL-1 225 39 94 88 58 0.55–0.87
TNF-α 325 38 89 75 62 0.39–0.74
sICAM-1 300 42 90 75 69 0.48–0.81
sVCAM >260 50 95 88 73 0.59–0.89
BALF
IL-1 136 32 87 75 50 0.35–0.70
TNF-α 82 32 92 88 42 0.44–0.77
sICAM-1 1540 35 88 75 58 0.38–0.73
sVCAM 392 42 86 63 73 0.45–0.79
PPV = positive predictive value; NPV = negative predictive value; CI = confidence interval; IL-1 = interleukin-1; TNF-α = tumour necrosis factor-
alpha; sICAM-1 = serumintercellular adhesion molecule-1; sVCAM = serum vascular adhesion molecule
Table 3 
Median (range) bronchoalveolar lavage fluid (BALF) and serum levels (pg/ml) of the measured cytokines and adhesion molecules in 
all patients (groups A + B + C) whether or not they survived
BALF Serum
Survivors (n = 38) Non-survivors (n = 27) Survivors (n = 38) Non-survivors (n = 27)
IL-1 215 (0–860) 410 (0–2030) 140 (3–558) 450** (3–908)
TNF-α 170 (0–2600) 222 (0–1428) 194 (94–790) 405* (60–1280)
sICAM-1 1140 (260–4620) 1520 (680–3780) 180 (66–360) 460** (66–1120)
sVCAM 312 (136–792) 356 (52–924) 150 (66–310) 380** (140–900)
*P < 0.05, **P < 0.0001 versus survivors group. Comparisons were done using the Mann-Whitney test. IL-1 = interleukin-1; TNF-α = tumour necro-
sis factor-alpha; sICAM-1 = serumintercellular adhesion molecule-1; sVCAM = serum vascular adhesion moleculeAvailable online http://respiratory-research.com/content/3/1/25
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The severity of lung injury seems to be related negatively 
with BALF IL-1, TNF-α and PaO2/FiO2 (Fig. 1C). The same 
was true for serum IL-1 and PaO2/FiO2 (Fig. 1D). All the 
studied molecules in the serum were positively correlated 
with the APACHE II score (Fig. 1B) as was BALF IL-1 (Fig. 
1A). It is probable that these cytokines are closely related 
to the extension of tissue damage and organ failure. In our 
patients, TNF-α was correlated with sVCAM and sICAM 
confirming a causal relationship to the extent of endotheli-
um activation. As there was no difference in the BALF lev-
els of these soluble adhesion molecules among the three 
groups, it seems that endothelial activation alone is not re-
lated to ARDS development, but correlates with the exten-
sion of tissue damage since they also correlated with the 
APACHE II score.
Patients with ARDS (group A) who died had elevated se-
rum levels of sICAM and sVCAM (Table 5) and these could 
be used as a survival predictor factor. Some investigators 
have reported that persistent elevation of inflammatory cy-
tokines may be predictive of ARDS development in at risk 
patients [14]. It is known that enhanced or prolonged re-
sponse with early phase inflammatory cytokines could pro-
duce tissue damage, while early response with early phase 
cytokines could lead to inefficient elimination of pathogens 
and to poor outcome [13,14,33]. Patients at risk who did 
not develop ARDS had lower serum levels of sVCAM com-
pared to those at risk who developed ARDS (Table 1). 
Since we did not examine our patients serially, we do not 
know if there is a critical value over time that could predict 
the course of the disease in these patients. However, the 
most interesting finding of this study is that the serum levels 
of the measured cytokines and adhesion molecules can 
predict survival. Indeed, and in contrast to BALF values, se-
rum levels of IL-1 and adhesion molecules exhibited a high 
positive predictive value, sensitivity and specificity for sur-
vival in all groups.
Conclusion
In conclusion, our data show that the two groups of mole-
cules (proinflammatory cytokines and adhesion molecules) 
studied in a single measurement, within 2 hours of hospital 
Table 4 
Median (range) bronchoalveolar lavage fluid (BALF) and serum levels (pg/ml) of the measured cytokines and adhesion molecules in 
acute respiratory distress syndrome patients (group A) whether or not they survived
BALF Serum
Survivors (n = 11) Non-survivors (n = 12) Survivors (n = 11) Non-survivors (n = 12)
IL-1 215 (10–435) 450 (0–2030) 130 (50–558) 400 (3–908)
TNF-α 600 (0–2600) 310 (0–1428) 362 (116–790) 212 (60–695)
sICAM-1 960 (540–2460) 980 (680–2140) 160 (66–300) 360* (66–1120)
sVCAM 312 (156–392) 356 (236–528) 100 (66–250) 380** (140–900)
*P < 0.05, **P < 0.01, versus survivors group. Comparisons were done using the Mann-Whitney test. IL-1 = interleukin-1; TNF-α = tumour necrosis 
factor-alpha; sICAM-1 = serumintercellular adhesion molecule-1; sVCAM = serum vascular adhesion molecule
Table 5 
Median (range) bronchoalveolar lavage fluid (BALF) and serum levels (pg/ml) of the measured cytokines and adhesion molecules in 
at risk patients who developed or did not develop acute respiratory distress syndrome (groups B + C)
BALF Serum
Survivors (n = 27) Non-survivors (n = 15) Survivors (n = 27) Non-survivors (n = 15)
IL-1 216 (0–860) 410 (0–630) 150 (3–306) 450** (400–563)
TNF-α 170 (0–680) 180 (0–481) 187 (94–775) 440* (170–1280)
sICAM-1 1250 (260–4620) 1860 (760–3780) 220 (66–360) 565** (350–900)
sVCAM 312 (136–792) 356 (52–924) 150 (66–310) 370** (300–720)
*P < 0.01, **P < 0.0001, versus survivors group. Comparisons were done using the Mann-Whitney test. IL-1 = interleukin-1; TNF-α = tumour 
necrosis factor-alpha; sICAM-1 = serumintercellular adhesion molecule-1; sVCAM = serum vascular adhesion moleculeRespiratory Research   Vol 3 No 1   Agouridakis et al.
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admission, are found at higher levels only in the serum of 
patients that died either with or without ARDS, providing a 
good negative predictive value for ARDS development 
both in serum and BALF. Further studies with serial BALF 
and serum measurements should be designed to investi-
gate the complex network of these molecules and their in-
hibitors in ARDS or at risk for ARDS and their value as 
predictive factors.
Abbreviations
ALI = acute lung injury; ARDS = acute respiratory distress syndrome; 
BALF = bronchoalveolar lavage fluid; ICAM-1= intercellular adhesion 
molecule-1; ICU = intensive care unit; IL-1 = interleukin-1; LFA-1 = lym-
phocyte function-associated antigen-1; LPS = lipopolysaccharide; NPV 
= negative predicted value; PEEP = positive end-expiratory pressure; 
PPV = positive predictive value; ROC = Receiver Operative Character-
istic; TNF-α = tumour necrosis factor-alpha; VCAM-1 = vascular adhe-
sion molecule-1.
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